Document is current
Any future updates will be listed below
-
Authors
Wolff, Jonas Holst https://orcid.org/0000-0001-5690-7603
Skov, Thomas Wisbech
Haslund, Didde https://orcid.org/0000-0002-9890-5814
Dorset, Sofie Rahbek
Revenfeld, Anne Louise S.
Aussel, Clotilde
Jørgensen, Sofie E.
Holm, Mette
Thomsen, Martin K. https://orcid.org/0000-0002-5055-7531
Ammann, Sandra https://orcid.org/0000-0003-0385-1890
Cathomen, Toni https://orcid.org/0000-0002-7757-4630
Mogensen, Trine H. https://orcid.org/0000-0002-1853-9704
Møller, Bjarne Kuno
Bak, Rasmus O. https://orcid.org/0000-0002-7383-0297
Mikkelsen, Jacob Giehm https://orcid.org/0000-0002-1322-3209
-
Funding
Funding for this research was provided by:
Innovationsfonden (8056-00010A)
Novo Nordisk Fonden (NNF220C0080684)
Carlsbergfondet (CF21-0363)
Deutsche Forschungsgemeinschaft (CA 311/4-1 & FANEDIT/EJPRD20-209)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 29 July 2025
First Online: 12 August 2025
Competing interests
: The authors declare the following competing interests: J.G.M. is a member of the Scientific Advisory Board of nChroma Bio. R.O.B. is a co-founder of and consultant to UNIKUM Tx and is co-inventor on patent number WO2016164356A1, titled “Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation” co-filed by The Board Of Trustees Of The Leland Stanford Junior University and Agilent Technologies, Inc. with the following inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, and Joel Myerson. The patent is granted and relates to the use of chemically modified guide RNAs used in the manuscript. R.O.B. reports research funding from Novo Nordisk. None of the companies were involved in the present study. The remaining authors declare no competing interests.
